Providers/Grant Support
This activity is supported in part by an independent education grant from UroGen Pharma.
Credits Available
- Physicians — maximum of 2.0 AMA PRA Category 1 Credits™
- Nurses — 2.0 Nursing Contact Hours
All other healthcare professionals completing this course will be issued a statement of participation
Target Audience
This activity is designed to meet the educational needs of Urologists, Urologic Oncologists, Medical Oncologists, Palliative Care, Pathologists, Advanced Practice Providers, Nurse Navigators and other healthcare professionals who treat patients with intermediate risk NMIBC.
Program Overview
This activity will cover the management of intermediate risk NMIBC, including diagnostic strategies, treatment advancements, BCG refractory cases, adjuvant therapies, with insights from leading experts in oncology and urology.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Employ strategies to enhance diagnostic accuracy for intermediate-risk bladder cancer, including applying risk stratification tools and integrating biomarkers into clinical workflows.
- Evaluate and implement alternative therapies to Bacillus Calmette-Guérin (BCG), including intravesical mitomycin, sustained-release formulations, and novel immunologic or gene therapies.
- Describe evidence-based surveillance protocols, balancing the need for disease monitoring with considerations of patient burden and healthcare costs.
- Understand the clinical utility of urinary biomarkers in predicting recurrence, guiding treatment selection, and monitoring treatment response in intermediate-risk bladder cancer.
- Recognize the importance of multidisciplinary care, fostering collaboration among urologists, oncologists, radiologists, and pathologists to optimize treatment planning and patient outcomes.
- Develop patient-centered treatment plans, tailoring therapy to individual clinical profiles while considering patient preferences and quality of life
Faculty
Dr. Kelly Bree
Dr. Kelly Bree is a urologic oncologist and Assistant Professor of Urology at MD Anderson Cancer Center in Houston, Texas.
Dr. Lindsey Herrel
Dr. Lindsey Herrel is a urologic oncologist practicing at the University of Michigan.
Dr. Amy Luckenbaugh
Dr. Amy Luckenbaugh is a urologist and an assistant professor in the Department of Urology at Vanderbilt University Medical Center in Nashville, Tennessee.
Dr. Ruchika Talwar
Dr. Ruchika Talwar is a urologic oncologist at Vanderbilt University Medical Center in Nashville, Tennessee.
Accreditation Statement
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
ACCME designates this enduring activity for a maximum of 2.0 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
Disclosures of Conflicts of Interest
Dr. Kelly Bree has no financial disclosures.
Dr. Lindsey Herrel has no financial disclosures.
Dr. Amy Luckenbaugh
- Consultant/Advisory Board: enGene
Dr. Ruchika Talwar
- Consultant/Advisory Board: ImmunityBio
Instructions For Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be immediately available to the participant.
Disclosure of Unlabeled Use
Postgraduate Institute for Medicine requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Contact Information
For CME questions please contact: [email protected]